Dhanusha Sabanathan - Concepedia

Author

Dhanusha Sabanathan

Also Known As

Aini Hyyti ÇÏinen, D. Sabanathan, D., Sabanathan, Damien Drubay, Denis Larsimont, Dhabusha Sabanathan, Dhanusha Sabanathan

Publications

846

Citations

H-Index

Concepts

All Affiliations

Macquarie University Sarah Cannon Westmead Hospital Tennessee Oncology University of Colorado Denver

About

Dhanusha Sabanathan is an author at Macquarie University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	99
2	Pharmacology	3	3	58
3	Immunology	2	2	40
4	Pathology	2	2	41
5	Health Sciences	1	1	14

Dhanusha Sabanathan

Publications

120

Citations

H-Index

Page 1

	Year	Citations
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring Dhanusha Sabanathan, Alison Y. Zhang, Peter Fox, Cancer Chemotherapy and Pharmacology Therapeutic Drug MonitoringUrologyOncologyGenitourinary CancerMedicine	2017	30
209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors Samuel J. Klempner, M. Beeram, Dhanusha Sabanathan, Annals of Oncology Sbt6050 MonotherapyMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2021	26
Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982–2011 Marina T. van Leeuwen, Howard Gurney, Jennifer Turner, Cancer Epidemiology Cancer EpidemiologyMalignant DiseaseMedicineSurgical PathologyCarcinoma	2016	15
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study. Kathleen N. Moore, Dhanusha Sabanathan, Yiqun Du, Journal of Clinical Oncology Her2 –Cancer ManagementImmunologyImmunotherapeuticsOncology	2023	14
382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer Nancy U. Lin, Virginia F. Borges, Manish R. Patel, Annals of Oncology Endocrine OncologyBreast OncologyPhase I/ii StudyMedicineHormonal Receptor	2023	14
Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826) Erika Hamilton, Jane Meisel, Carlos Alemany, European Journal of Cancer	2022	11
Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal? Dhanusha Sabanathan, John Park, Manuel Márquez, The Oncologist	2017	10

Page 1